Stem Cell Treatment of Retinal Transplant
The retinal pigment epithelium (RPE) is a layer of pigmented cells sandwiched between the visual retinal cells, called photoreceptors, and the nourishing blood vessels at the back of the eye. The RPE provides essential support to the retinal photoreceptors and is critical for normal vision. Deterioration of the RPE plays a central role in the progression of diseases such as age-related macular degeneration and sub-types of retinitis pigmentosa. These conditions are associated with a progressive loss of vision that often leads to blindness.
GIOSTAR has the ability derive RPE-like cells from ES cell, which is identified by their characteristic black pigment, exhibited multiple biological properties and genetic markers that define authentic RPE cells. Further, the cells successfully delayed deterioration of retinal structure and function when they were transplanted into eye. GIOSTAR is developing the technology to treat the blindness related with retinal degeneration.
What Sets Us Apart
- Headquartered in USA.
- The founder is leading stem cell scientist credited with helping in setting up the stem cell research labs at top research institutions in the US including Salk Research Institute, Sanford-Burnham Institute, UCI, UCSD.
- Scientific And Medical Advisers/Consultants are comprising of luminaries who have worked at University of California, San Diego (UCSD), University of California Irvine (UCI).
- State of the art and the first private hospital in the India inaugurated by (then Chief Minister of State of Gujarat) and present Prime Minister of India.
- One of the world’s largest Stem Cell Hospital funded by the government of Gujarat, India.
Disclaimer : Results may vary for each patient. GIOSTAR practice the application of stem cell therapy within the legal regulations of each country.
